2018 Asco Annual Meeting

2018 Asco Annual Meeting

GBT attended the 2018 ASCO Annual Meeting in Chicago.

Montevideo, Uruguay June 6, 2018. Between June 1 to June 5, GBT Grupo Biotoscana (GBT) participated in the 2018 ASCO Annual Meeting (American Society of Clinical Oncology) that attracted the best and most relevant professionals of the oncology world to the McCormick Place convention center in Chicago. This edition of the biggest event about oncology reached more than 40,000 doctors and professionals focused on discuss and listen about the latest innovations in the fight against cancer.

During ASCO, it became even more clear the size and importance of not only of the products GBT has licensed, but also the relevance of our partners. An example of this is the research pipeline being conducted by Eisai. LENVIMA® was always on spotlight during this edition of the conference, especially because of the collaboration between Eisai and Merck (MSD), about the current studies of the combination of LENVIMA® and KEYTRUDA®.

The GBT team also had the opportunity to attend a series of plenary sessions on breast and pancreatic cancer. During the lessons, it was evidenced that the products that we have in our pipeline are taken as the standard of choice in the main medical consensuses. HALAVEN® and ABRAXANE® have been evaluated within their indications as the standard of chemotherapeutic treatment versus new therapies in combination, demonstrating that they are currently the standard of care in the treatment of these diseases.